Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention
Eunseuk Lee, Ji Hyun Lee, Hye Ryeon Kim, Seok Jae Huh, Suee Lee, Sung-Yong Oh, Sung-Hyun Kim, Hojin Lee · 2026
Read Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention by Eunseuk Lee, Ji Hyun Lee, Hye Ryeon Kim, Seok Jae Huh, Suee Lee, Sung-Yong Oh, Sung-Hyun Kim, Hojin Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13260542.txt.
Description
Eunseuk Lee and co-authors wrote a 2026 review of infection problems after CAR T-cell therapy, a treatment that engineers a patient's immune cells to attack B-cell cancers. Infections are a major cause of illness and death not due to relapse. Risk comes from a long, layered weakening of immunity: chemotherapy before treatment, low blood cell counts, and loss of helper T cells and antibody-producing B cells. Drugs used to manage treatment side effects add more risk.
Bacterial infections lead early, while viral infections and others that strike when immunity is low grow prominent later, above all when immune recovery is slow. One product type, BCMA-directed therapy, carries a higher infection burden, linked to deep plasma cell loss. Prevention combines antiviral drugs and pneumonia prevention, antibacterial and antifungal cover, antibody top-ups, and vaccines timed to immune recovery. The review sums up world guideline advice.
Catalog record
| CREATOR | Eunseuk Lee, Ji Hyun Lee, Hye Ryeon Kim, Seok Jae Huh, Suee Lee, Sung-Yong Oh, Sung-Hyun Kim, Hojin Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61104 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |